FR2867980B1 - Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta - Google Patents

Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta

Info

Publication number
FR2867980B1
FR2867980B1 FR0402972A FR0402972A FR2867980B1 FR 2867980 B1 FR2867980 B1 FR 2867980B1 FR 0402972 A FR0402972 A FR 0402972A FR 0402972 A FR0402972 A FR 0402972A FR 2867980 B1 FR2867980 B1 FR 2867980B1
Authority
FR
France
Prior art keywords
dna polymerase
polymerase inhibitor
masticadienonic acid
beta dna
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0402972A
Other languages
English (en)
Other versions
FR2867980A1 (fr
Inventor
Georges Massiot
Christophe Long
Frederic Ausseil
Martine Knibiehler
Yvan Canitrot
Jean Sebastien Hoffmann
Christophe Cazaux
Pierre Benaim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Pierre Fabre Medicament SA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Pierre Fabre Medicament SA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR0402972A priority Critical patent/FR2867980B1/fr
Priority to PCT/FR2005/000701 priority patent/WO2005094837A1/fr
Publication of FR2867980A1 publication Critical patent/FR2867980A1/fr
Application granted granted Critical
Publication of FR2867980B1 publication Critical patent/FR2867980B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0402972A 2004-03-23 2004-03-23 Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta Expired - Fee Related FR2867980B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR0402972A FR2867980B1 (fr) 2004-03-23 2004-03-23 Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta
PCT/FR2005/000701 WO2005094837A1 (fr) 2004-03-23 2005-03-23 Utilisation de l’acide masticadienonique en tant qu’inhibiteur de l’adn polymerase beta

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0402972A FR2867980B1 (fr) 2004-03-23 2004-03-23 Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta

Publications (2)

Publication Number Publication Date
FR2867980A1 FR2867980A1 (fr) 2005-09-30
FR2867980B1 true FR2867980B1 (fr) 2006-07-14

Family

ID=34944453

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0402972A Expired - Fee Related FR2867980B1 (fr) 2004-03-23 2004-03-23 Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta

Country Status (2)

Country Link
FR (1) FR2867980B1 (fr)
WO (1) WO2005094837A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101875984B1 (ko) 2010-09-07 2018-07-06 레제네라 파마 리미티드 매스틱 검의 산성 추출물을 포함하는 조성물
KR20180054821A (ko) 2015-09-24 2018-05-24 레제네라 파마 리미티드 트리테르페노이드 포함 조성물
ES2904263T3 (es) 2015-09-24 2022-04-04 Regenera Pharma Ltd Composiciones que comprenden triterpenoides para el tratamiento de la enfermedad de Alzheimer y la enfermedad de Parkinson
BR112019004488A2 (pt) 2016-09-08 2019-05-28 Regenera Pharma Ltd composições compreendendo triterpenoides e utilizações das mesmas para tratamento de neuropatia ótica
CN109922798A (zh) 2016-09-08 2019-06-21 瑞吉纳拉制药公司 包括乳香胶的酸性提取物的组合物及其用于治疗视神经病变的用途
CN108715845B (zh) * 2018-05-15 2021-09-24 郑州大学 一种食管上皮组织polβ特异性敲除小鼠食管癌前病变模型的构建方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003241345A1 (en) * 2002-05-01 2003-11-17 Lavipharm S.A. Use of mastic and its components for the control of microbial infections

Also Published As

Publication number Publication date
WO2005094837A1 (fr) 2005-10-13
FR2867980A1 (fr) 2005-09-30

Similar Documents

Publication Publication Date Title
DK2066684T3 (da) 5´-Modificerede bicycliske nukleinsyreanaloge
FR2902324B1 (fr) Utilisation d'acide ellagique pour le traitement de la canitie
BRPI0819193A2 (pt) uso de oligonucleotídeos com bases modificadas na hibridização de ácidos nucleicos.
HK1154636A1 (en) Preparation of templates for nucleic acid sequencing
NO20053892D0 (no) Virale polymeraseinhibitorer
DK2176280T3 (da) 6-Disubstituerede bicykliske nukleinsyreanaloge
DE602004001461D1 (de) Verstärkte polyoxymethylen-polymilchsäure zusammensetzungen
NO20054747D0 (no) Fosforsyreester-demulgerende sammensetning
DK2135949T3 (da) MCP-1-bindende nukleinsyrer
DE602005024566D1 (de) Verfahren zur herstellung von 2-amino-5-iodobenzoesäure
FR2909280B1 (fr) Utilisation de l'acide gamma-aminobutyrique en tant qu'agent depigmentant
FR2867980B1 (fr) Utilisation de l'acide masticadienonique en tant qu'inhibiteur de l'adn polymerase beta
DE602006006692D1 (de) Konzentrierte flüssige triazolfungizidformulierungen
DE502005009157D1 (de) Verfahren zur herstellung von alkenylbernsteinsäureanhydriden
GB0406863D0 (en) Nucleic acid sequencing
DE602006020024D1 (de) Rückgewinnung von schwefelsäure
DE60329036D1 (de) Ökologisches verfahren zur herstellung von brombenzol
MA28996B1 (fr) Nouvelle utilisation de l'acide 2-hydroxy-4-methylthyiobutanoïque(hmte)
ITTO20060063A1 (it) Corredo per l'amplificazione di acidi nucleici.
FR2850103B1 (fr) Procede de preparation d'esters d'acide (meth)acrylique
DE602005012173D1 (de) Verfahren zur Herstellung von extrachromosomalen Nukleinsäuremolekülen
IS8176A (is) DNA byggðar aptamerur fyrir mennskt katepsín G
ITRM20030416A0 (it) Procedimento per la purificazione di acidi solforici.
DK1841855T3 (da) Anvendelse af blandinger involveret i biosyntese af nukleinsyrer til forøgelse af bakteriekulturers udbytte og stabilitet
FR2884389B1 (fr) Scarificateur de patons adapte pour diminuer la penibilite de la scarification

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20071130